Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · 50 mg & 850 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Reddy-Sitagliptin and Metformin HCl · DIN 02540126
Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2025-04-30
Health Canada: Marketed since 2023-10-05 · brand REDDY-SITAGLIPTIN AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Dr reddy's laboratories ltd · schedule Prescription
Reddy-Sitagliptin and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02540126)
Source record
DIN 02540126: Reddy-Sitagliptin and Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id DRR
Source form: Tab; strength: 50mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540126
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102883
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446
Janumet · DIN 02333864 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446
Sitagliptin-Metformin · DIN 02529165 · $0.4446
Sitagliptin/Metformin · DIN 02560453 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: not checked (no credentials)